vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Seritage Growth Properties (SRG). Click either name above to swap in a different company.
Seritage Growth Properties is the larger business by last-quarter revenue ($4.2M vs $3.9M, roughly 1.1× Opus Genetics, Inc.). On growth, Seritage Growth Properties posted the faster year-over-year revenue change (-4.9% vs -10.2%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -15.0%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Seritage Growth Properties is a U.S.-headquartered publicly traded real estate investment trust. It owns, redevelops, and manages a diversified portfolio of retail, residential, and mixed-use commercial properties across key U.S. markets, leasing spaces to retail, dining, and service sector tenants.
IRD vs SRG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.2M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -10.2% | -4.9% |
| Net Profit YoY | 53.0% | 55.2% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.2M | ||
| Q3 25 | $3.1M | $4.8M | ||
| Q2 25 | $2.9M | $4.7M | ||
| Q1 25 | $4.4M | $4.6M | ||
| Q4 24 | $4.3M | $4.4M | ||
| Q3 24 | $3.9M | $3.3M | ||
| Q2 24 | $1.1M | $4.2M | ||
| Q1 24 | $1.7M | $5.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-17.5M | $-12.4M | ||
| Q2 25 | $-7.4M | $-28.5M | ||
| Q1 25 | $-8.2M | $-22.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.5M | $-22.0M | ||
| Q2 24 | $-7.8M | $-101.2M | ||
| Q1 24 | $-7.1M | $-19.0M |
| Q4 25 | — | — | ||
| Q3 25 | -269.9% | -258.0% | ||
| Q2 25 | -309.0% | -610.2% | ||
| Q1 25 | -227.2% | -486.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -207.1% | -673.2% | ||
| Q2 24 | -748.9% | -2366.1% | ||
| Q1 24 | -450.5% | -328.7% |
| Q4 25 | — | — | ||
| Q3 25 | -566.9% | -259.6% | ||
| Q2 25 | -257.5% | -612.6% | ||
| Q1 25 | -187.5% | -482.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -194.6% | -675.9% | ||
| Q2 24 | -698.3% | -2401.0% | ||
| Q1 24 | -415.3% | -328.9% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.25 | $-0.24 | ||
| Q2 25 | $-0.12 | $-0.53 | ||
| Q1 25 | $-0.24 | $-0.42 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | $-0.41 | ||
| Q2 24 | $-0.30 | $-1.82 | ||
| Q1 24 | $-0.29 | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $48.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $331.4M |
| Total Assets | $50.2M | $393.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $48.1M | ||
| Q3 25 | $30.8M | $51.5M | ||
| Q2 25 | $32.4M | $71.8M | ||
| Q1 25 | $41.8M | $94.3M | ||
| Q4 24 | $30.3M | $85.2M | ||
| Q3 24 | $36.6M | $85.6M | ||
| Q2 24 | $41.4M | $86.7M | ||
| Q1 24 | $47.2M | $114.9M |
| Q4 25 | $15.3M | $331.4M | ||
| Q3 25 | $6.0M | $337.7M | ||
| Q2 25 | $17.5M | $351.4M | ||
| Q1 25 | $5.1M | $381.1M | ||
| Q4 24 | $6.7M | $404.5M | ||
| Q3 24 | $34.3M | $417.5M | ||
| Q2 24 | $40.6M | $440.4M | ||
| Q1 24 | $46.1M | $542.4M |
| Q4 25 | $50.2M | $393.8M | ||
| Q3 25 | $36.1M | $558.6M | ||
| Q2 25 | $38.7M | $575.7M | ||
| Q1 25 | $48.2M | $649.7M | ||
| Q4 24 | $36.9M | $677.8M | ||
| Q3 24 | $40.4M | $735.0M | ||
| Q2 24 | $44.8M | $758.3M | ||
| Q1 24 | $51.8M | $914.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-34.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-34.9M | ||
| Q3 25 | $-6.2M | $-12.5M | ||
| Q2 25 | $-10.3M | $-12.0M | ||
| Q1 25 | $-9.0M | $-9.2M | ||
| Q4 24 | $-25.6M | $-53.5M | ||
| Q3 24 | $-5.1M | $-15.5M | ||
| Q2 24 | $-7.3M | $-7.5M | ||
| Q1 24 | $-5.7M | $-16.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
